1921
Volume 94, Issue 4
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract

parasites cause a broad range of disease, with cutaneous afflictions being, by far, the most prevalent. Variations in disease severity and symptomatic spectrum are mostly associated to parasite species. One risk factor for the severity and emergence of leishmaniasis is immunosuppression, usually arising by coinfection of the patient with human immunodeficiency virus (HIV). Interestingly, several species of have been shown to bear an endogenous cytoplasmic dsRNA virus (LRV) of the family, and recently we correlated the presence of LRV1 within parasites to an exacerbation murine leishmaniasis and with an elevated frequency of drug treatment failures in humans. This raises the possibility of further exacerbation of leishmaniasis in the presence of both viruses, and here we report a case of cutaneous leishmaniasis caused by bearing LRV1 with aggressive pathogenesis in an HIV patient. LRV1 was isolated and partially sequenced from skin and nasal lesions. Genetic identity of both sequences reinforced the assumption that nasal parasites originate from primary skin lesions. Surprisingly, combined antiretroviral therapy did not impact the devolution of infection. The infection was successfully treated through administration of liposomal amphotericin B.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.15-0803
2016-04-06
2017-11-22
Loading full text...

Full text loading...

/deliver/fulltext/14761645/94/4/840.html?itemId=/content/journals/10.4269/ajtmh.15-0803&mimeType=html&fmt=ahah

References

  1. Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J, Jannin J, den Boer M, WHO Leishmaniasis Control Team; , 2012. Leishmaniasis worldwide and global estimates of its incidence. PLoS One 7: e35671.[Crossref]
  2. Zangger H, Hailu A, Desponds C, Lye LF, Akopyants NS, Dobson DE, Ronet C, Ghalib H, Beverley SM, Fasel N, , 2014. Leishmania aethiopica field isolates bearing an endosymbiontic dsRNA virus induce pro-inflammatory cytokine response. PLoS Negl Trop Dis 8: e2836.[Crossref]
  3. Hartley MA, Drexler S, Ronet C, Beverley SM, Fasel N, , 2014. The immunological, environmental, and phylogenetic perpetrators of metastatic leishmaniasis. Trends Parasitol 30: 412422.[Crossref]
  4. Tarr PI, Aline RF, Jr Smiley BL, Scholler J, Keithly J, Stuart K, , 1988. LR1: a candidate RNA virus of Leishmania . Proc Natl Acad Sci USA 85: 95729575.[Crossref]
  5. Widmer G, Comeau AM, Furlong DB, Wirth DF, Patterson JL, , 1989. Characterization of a RNA virus from the parasite Leishmania . Proc Natl Acad Sci USA 86: 59795982.[Crossref]
  6. Salinas G, Zamora M, Stuart K, Saravia N, , 1996. Leishmania RNA viruses in Leishmania of the Viannia subgenus. Am J Trop Med Hyg 54: 425429.
  7. Ives A, Ronet C, Prevel F, Ruzzante G, Fuertes-Marraco S, Schutz F, Zangger H, Revaz-Breton M, Lye LF, Hickerson SM, Beverley SM, Acha-Orbea H, Launois P, Fasel N, Masina S, , 2011. Leishmania RNA virus controls the severity of mucocutaneous leishmaniasis. Science 331: 775778.[Crossref]
  8. Carvalho EM, Johnson WD, Barreto E, Marsden PD, Costa JL, Reed S, Rocha H, , 1985. Cell mediated immunity in American cutaneous and mucosal leishmaniasis. J Immunol 135: 41444148.
  9. Silveira FT, Lainson R, De Castro Gomes CM, Laurenti MD, Corbett CE, , 2009. Immunopathogenic competences of Leishmania (V.) braziliensis and L. (L.) amazonensis in American cutaneous leishmaniasis. Parasite Immunol 31: 423431.[Crossref]
  10. Bourreau E, Ginouves M, Prevot G, Hartley MA, Gangneux JP, Robert-Gangneux F, Dufour J, Sainte-Marie D, Bertolotti A, Pratlong F, Martin R, Schutz F, Couppie P, Fasel N, Ronet C, , 2015. Presence of Leishmania RNA virus 1 in Leishmania guyanensis increases the risk of first-line treatment failure and symptomatic relapse. J Infect Dis 213: 105111.[Crossref]
  11. Adaui V, Lye LF, Akopyants NS, Zimic M, Llanos-Cuentas A, Garcia L, Maes I, De Doncker S, Dobson DE, Arevalo J, Dujardin JC, Beverley SM, , 2015. Association of the endobiont double-stranded RNA virus LRV1 with treatment failure for human leishmaniasis caused by Leishmania braziliensis in Peru and Bolivia. J Infect Dis 213: 112121.[Crossref]
  12. Alvar J, Aparicio P, Aseffa A, Den Boer M, Canavate C, Dedet JP, Gradoni L, Ter Horst R, Lopez-Velez R, Moreno J, , 2008. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 21: 334359.[Crossref]
  13. el Tai NO, Osman OF, el Fari M, Presber W, Schonian G, , 2000. Genetic heterogeneity of ribosomal internal transcribed spacer in clinical samples of Leishmania donovani spotted on filter paper as revealed by single-strand conformation polymorphisms and sequencing. Trans R Soc Trop Med Hyg 94: 575579.[Crossref]
  14. Zangger H, Ronet C, Desponds C, Kuhlmann FM, Robinson J, Hartley MA, Prevel F, Castiglioni P, Pratlong F, Bastien P, Muller N, Parmentier L, Saravia NG, Beverley SM, Fasel N, , 2013. Detection of Leishmania RNA virus in Leishmania parasites. PLoS Negl Trop Dis 7: e2006.[Crossref]
  15. Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S, , 2007. Cutaneous leishmaniasis. Lancet Infect Dis 7: 581596.[Crossref]
  16. Amato VS, Tuon FF, Bacha HA, Neto VA, Nicodemo AC, , 2008. Mucosal leishmaniasis. Current scenario and prospects for treatment. Acta Trop 105: 19.[Crossref]
  17. Machado PR, Rosa ME, Guimaraes LH, Prates FV, Queiroz A, Schriefer A, Carvalho EM, , 2015. Treatment of disseminated leishmaniasis with liposomal amphotericin B. Clin Infect Dis 61: 945949.[Crossref]
  18. Amato VS, Nicodemo AC, Amato JG, Boulos M, Neto VA, , 2000. Mucocutaneous leishmaniasis associated with HIV infection treated successfully with liposomal amphotericin B (AmBisome). J Antimicrob Chemother 46: 341342.[Crossref]
  19. Costa JM, Marsden PD, Llanos-Cuentas EA, Netto EM, Carvalho EM, Barral A, Rosa AC, Cuba CC, Magalhaes AV, Barreto AC, , 1986. Disseminated cutaneous leishmaniasis in a field clinic in Bahia, Brazil: a report of eight cases. J Trop Med Hyg 89: 319323.
  20. Carvalho EM, Barral A, Costa JM, Bittencourt A, Marsden P, , 1994. Clinical and immunopathological aspects of disseminated cutaneous leishmaniasis. Acta Trop 56: 315325.[Crossref]
  21. Turetz ML, Machado PR, Ko AI, Alves F, Bittencourt A, Almeida RP, Mobashery N, Johnson WD, Jr Carvalho EM, , 2002. Disseminated leishmaniasis: a new and emerging form of leishmaniasis observed in northeastern Brazil. J Infect Dis 186: 18291834.[Crossref]
  22. Machado ES, Braga M da P, Da Cruz AM, Coutinho SG, Vieira AR, Rutowitsch MS, Cuzzi-Maya T, Grimaldi G, Jr Menezes JA, , 1992. Disseminated American muco-cutaneous leishmaniasis caused by Leishmania braziliensis braziliensis in a patient with AIDS: a case report. Mem Inst Oswaldo Cruz 87: 487492.[Crossref]
  23. Lindoso JA, Barbosa RN, Posada-Vergara MP, Duarte MI, Oyafuso LK, Amato VS, Goto H, , 2009. Unusual manifestations of tegumentary leishmaniasis in AIDS patients from the New World. Br J Dermatol 160: 311318.[Crossref]
  24. Goto H, Lindoso JA, , 2010. Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. Expert Rev Anti Infect Ther 8: 419433.[Crossref]
  25. Couppie P, Clyti E, Sobesky M, Bissuel F, Del Giudice P, Sainte-Marie D, Dedet JP, Carme B, Pradinaud R, , 2004. Comparative study of cutaneous leishmaniasis in human immunodeficiency virus (HIV)-infected patients and non-HIV-infected patients in French Guiana. Br J Dermatol 151: 11651171.[Crossref]
  26. Guerra JA, Coelho LI, Pereira FR, Siqueira AM, Ribeiro RL, Almeida TM, Lacerda MV, Barbosa M, Talhari S, , 2011. American tegumentary leishmaniasis and HIV-AIDS association in a tertiary care center in the Brazilian Amazon. Am J Trop Med Hyg 85: 524527.[Crossref]
  27. de Souza e Souza I, Naiff RD, Guimaraes TC, Naiff MF, Cupolillo E, Rodrigues WA, Schettini AP, , 1998. American cutaneous leishmaniasis due to Leishmania (Viannia) guyanensis as an initial clinical presentation of human immunodeficiency virus infection. J Eur Acad Dermatol Venereol 10: 214217.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.15-0803
Loading
/content/journals/10.4269/ajtmh.15-0803
Loading

Data & Media loading...

  • Received : 09 Nov 2015
  • Accepted : 17 Dec 2015

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error